BioSens8 today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements in artificial intelligence (AI) and data sciences.
BioSens8 is expanding beyond the glucometer and enabling holistic and personalized health monitoring. It is doing so by engineering continuous and non-invasive monitors for hormones, neurotransmitters, and drug use to give unprecedented insight into the human body’s health. A deployed multiplexed wearable will open the door to truly personalized medicine and proactive, data-driven health decisions.
Joining NVIDIA Inception will help drive BioSens8’s business forward through go-to-market support, training, and technological assistance to lay the foundation for implementing AI and machine learning into its vast and novel data sets. Most notably, these include mining health data to deliver prognostic indications and detect abnormalities for preemptive responses. The program will also offer BioSens8 the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
“BioSens8 is opening the door to immense amounts of information about our body’s state which was never before available,” said Uroš Kuzmanović, CEO of BioSens8. “I’m thrilled to have joined NVIDIA Inception. The moment is now for us to implement infrastructure to be able to mine this data and provide value to our customers, and there’s no better collaborator to do it with than NVIDIA. I’m looking forward to working with them and their network to help reshape how we approach healthcare.”
NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.
Source:
BioSens8, Inc.
Company Contact:
Uroš Kuzmanović, PhD
CEO & Co-Founder
コメント